Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 127Carcinoma, Non-Small-Cell Lung 57Squamous Cell Carcinoma of Head and Neck 46Neoplasms 41Head and Neck Neoplasms 38Neoplasm Metastasis 31Pancreatic Neoplasms 15Colonic Neoplasms 14Lung Neoplasms 13Carcinoma, Squamous Cell 13Breast Neoplasms 13Rectal Neoplasms 12Recurrence 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Melanoma 7Stomach Neoplasms 6Carcinoma, Renal Cell 6Carcinoma 6Solid Tumors 5Gastrointestinal Neoplasms 5Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Neoplasms, Squamous Cell 4Laryngeal Diseases 4Advanced Solid Tumor 4Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Pancreatic Ductal 3Uterine Cervical Neoplasms 2

Interventions

Gemcitabine 28pembrolizumab 24Cisplatin 24Fluorouracil 11Leucovorin 10Oxaliplatin 8Nivolumab 7Capecitabine 6Irinotecan 5Drug Therapy 5pemigatinib 4futibatinib 4Paclitaxel 4Carboplatin 4ivosidenib 3durvalumab 3derazantinib 3Folfox protocol 3Bevacizumab 3zanidatamab 2spartalizumab 2olutasidenib 2lenvatinib 2infigratinib 2fludarabine 2budigalimab 2Trastuzumab 2Ipilimumab 2Injections 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cholangiocarcinoma × Cetuximab × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡